Summary
79.22 2.11(2.73%)05/21/2024
Astrazeneca plc (AZN)
Astrazeneca plc (AZN)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 0.74 | 0.58 | 12.73 | 14.68 | 19.98 | 1.98 | 124.27 | 4,211.86 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 76.32 | |
| Open | 76.43 | |
| High | 76.47 | |
| Low | 75.92 | |
| Volume | 6,663,140 | |
| Change | 0.56 | |
| Change % | 0.74 | |
| Avg Volume (20 Days) | 7,003,775 | |
| Volume/Avg Volume (20 Days) Ratio | 0.95 | |
| 52 Week Range | 60.47 - 76.80 | |
| Price vs 52 Week High | -0.63% | |
| Price vs 52 Week Low | 26.21% | |
| Range | -0.14 | |
| Gap Up/Down | 0.50 | |
Fundamentals | ||
| Market Capitalization (Mln) | 239,078 | |
| EBIDTA | 15,802,999,808 | |
| PE Ratio | 38.2079 | |
| PEG Ratio | 0.8861 | |
| WallStreet Target Price | 82.74 | |
| Book Value | 24.1740 | |
| Earnings Per Share | 2.0200 | |
| EPS Estimate Current Quarter | 1.2200 | |
| EPS Estimate Next Quarter | 1.3200 | |
| EPS Estimate Current Year | 4.0600 | |
| EPS Estimate Next Year | 5.7200 | |
| Diluted EPS (TTM) | 2.0200 | |
| Revenues | ||
| Profit Marging | 0.1330 | |
| Operating Marging (TTM) | 0.2611 | |
| Return on asset (TTM) | 0.0704 | |
| Return on equity (TTM) | 0.1729 | |
| Revenue TTM | 47,610,998,784 | |
| Revenue per share TTM | 2.5512 | |
| Quarterly Revenue Growth (YOY) | 0.1650 | |
| Quarterly Earnings Growth (YOY) | 0.2070 | |
| Gross Profit (TTM) | 35,732,000,000 | |
| Dividends | ||
| Dividend Share | 2.9000 | |
| Dividend Yield | 0.0188 | |
| Valuations | ||
| Trailing PE | 38.2079 | |
| Forward PE | 16.3132 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 5.4598 | |
| Revenue Enterprise Value | 5.1971 | |
| EBITDA Enterprise Value | 17.7384 | |
| Shares | ||
| Shares Outstanding | 3,100,470,016 | |
| Shares Float | 1,543,222,230 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 0.01 | |
| Institutions (%) | 16.86 | |
05/21 13:36 EST - zacks.com
AstraZeneca (AZN) Plans to Generate $80B in Revenues by 2030
AstraZeneca (AZN) targets $80 billion in total revenues by 2030. It expects to launch 20 new medicines.
AstraZeneca (AZN) Plans to Generate $80B in Revenues by 2030
AstraZeneca (AZN) targets $80 billion in total revenues by 2030. It expects to launch 20 new medicines.
05/21 09:11 EST - proactiveinvestors.co.uk
AstraZeneca's new 2030 targets are bold attempt to reach for the stars, say analysts
After AstraZeneca PLC (LSE:AZN) unveiled new sales and profit targets for the end of the decade, analysts were mildly impressed by the ambition to "shoot for the stars". Starting with the bare numbers, UBS noted that the new target to achieve $80 billion in total revenue by 2030 compared to consensus core revenue of $67 billion and its own forecast of $72 billion.
AstraZeneca's new 2030 targets are bold attempt to reach for the stars, say analysts
After AstraZeneca PLC (LSE:AZN) unveiled new sales and profit targets for the end of the decade, analysts were mildly impressed by the ambition to "shoot for the stars". Starting with the bare numbers, UBS noted that the new target to achieve $80 billion in total revenue by 2030 compared to consensus core revenue of $67 billion and its own forecast of $72 billion.
05/21 04:38 EST - cnbc.com
AstraZeneca targets $80 billion in total revenue by 2030 with release of 20 new medicines
Pharmaceutical company AstraZeneca is planning to increase its total revenue by 75% and release 20 new medicines by 2030, including cancer treatments.
AstraZeneca targets $80 billion in total revenue by 2030 with release of 20 new medicines
Pharmaceutical company AstraZeneca is planning to increase its total revenue by 75% and release 20 new medicines by 2030, including cancer treatments.
05/21 04:19 EST - marketwatch.com
AstraZeneca kicks off ‘new era of growth' with aim to hit $80 billion of sales by 2030
AstraZeneca on Tuesday outlined ambitions to almost double its sales over the next six years by launching 20 new medicines by 2030.
AstraZeneca kicks off ‘new era of growth' with aim to hit $80 billion of sales by 2030
AstraZeneca on Tuesday outlined ambitions to almost double its sales over the next six years by launching 20 new medicines by 2030.
05/21 03:15 EST - proactiveinvestors.com
AstraZeneca aims to boost revenues to $80bn by 2030
AstraZeneca PLC (LSE:AZN) aims to grow its revenue by about 75% to $80 billion by 2030, driven by the launch of 20 new medicines and growth in its oncology, biopharmaceuticals, and rare disease portfolios. In an announcement made ahead of the drug giant's investor day event on Tuesday, CEO Pascal Soriot, who has revitalised the company's drug pipeline over the past decade, highlighted potential blockbusters such as the lung cancer drug Tagrisso, Calquence for leukaemia, and diabetes treatment Farxiga.
AstraZeneca aims to boost revenues to $80bn by 2030
AstraZeneca PLC (LSE:AZN) aims to grow its revenue by about 75% to $80 billion by 2030, driven by the launch of 20 new medicines and growth in its oncology, biopharmaceuticals, and rare disease portfolios. In an announcement made ahead of the drug giant's investor day event on Tuesday, CEO Pascal Soriot, who has revitalised the company's drug pipeline over the past decade, highlighted potential blockbusters such as the lung cancer drug Tagrisso, Calquence for leukaemia, and diabetes treatment Farxiga.
05/21 02:14 EST - reuters.com
AstraZeneca aims to deliver $80 billion in total revenue by 2030
AstraZeneca laid out its target to deliver $80 billion in total revenue by 2030 on Tuesday, boosted by the expected launch of 20 new medicines and through growth in its existing oncology, biopharmaceuticals and rare disease portfolio.
AstraZeneca aims to deliver $80 billion in total revenue by 2030
AstraZeneca laid out its target to deliver $80 billion in total revenue by 2030 on Tuesday, boosted by the expected launch of 20 new medicines and through growth in its existing oncology, biopharmaceuticals and rare disease portfolio.
05/21 02:00 EST - businesswire.com
AstraZeneca sets ambition to deliver $80 billion Total Revenue by 2030 and sustained growth post 2030
CAMBRIDGE, England--(BUSINESS WIRE)--Investor Day 2024.
AstraZeneca sets ambition to deliver $80 billion Total Revenue by 2030 and sustained growth post 2030
CAMBRIDGE, England--(BUSINESS WIRE)--Investor Day 2024.
05/20 13:34 EST - investorplace.com
7 Biotech Stocks That Could Breathe New Life Into Your Portfolio
Fundamentally, one of the biggest advantages of biotech stocks to buy centers on the underlying prioritization. While the media focuses on attaining wealth, that doesn't mean much if you don't have health.
7 Biotech Stocks That Could Breathe New Life Into Your Portfolio
Fundamentally, one of the biggest advantages of biotech stocks to buy centers on the underlying prioritization. While the media focuses on attaining wealth, that doesn't mean much if you don't have health.
05/20 11:46 EST - zacks.com
AstraZeneca (AZN) to Build $1.5B Cancer Drug Plant in Singapore
This new plant will be AstraZeneca's (AZN) first manufacturing facility for producing novel antibody drug conjugates from start to finish. It is scheduled to open in 2029.
AstraZeneca (AZN) to Build $1.5B Cancer Drug Plant in Singapore
This new plant will be AstraZeneca's (AZN) first manufacturing facility for producing novel antibody drug conjugates from start to finish. It is scheduled to open in 2029.
05/20 06:55 EST - proactiveinvestors.co.uk
AstraZeneca lays out plans for $1.5bn Singapore plant
AstraZeneca PLC (LSE:AZN) has unveiled plans to build a US$1.5 billion (£1.2 billion) production plant in Singapore. This will be used to manufacture cancer-killing drugs known as antibody-drug conjugates, AstraZeneca announced on Monday.
AstraZeneca lays out plans for $1.5bn Singapore plant
AstraZeneca PLC (LSE:AZN) has unveiled plans to build a US$1.5 billion (£1.2 billion) production plant in Singapore. This will be used to manufacture cancer-killing drugs known as antibody-drug conjugates, AstraZeneca announced on Monday.
05/20 02:11 EST - reuters.com
AstraZeneca plans to build $1.5 bln manufacturing facility in Singapore
AstraZeneca is planning to build a $1.5 billion manufacturing facility in Singapore in an effort to enhance its antibody drug conjugates (ADCs) portfolio, the drugmaker said on Monday.
AstraZeneca plans to build $1.5 bln manufacturing facility in Singapore
AstraZeneca is planning to build a $1.5 billion manufacturing facility in Singapore in an effort to enhance its antibody drug conjugates (ADCs) portfolio, the drugmaker said on Monday.
05/19 17:17 EST - businesswire.com
New data presented at ATS 2024 show the potential of TEZSPIRE to play a role in the future treatment of chronic obstructive pulmonary disease
WILMINGTON, Del.--(BUSINESS WIRE)--The Phase IIa COURSE trial was a proof-of-concept study in people with moderate to very severe chronic obstructive pulmonary disease (COPD) with a broad range of blood eosinophil counts (BEC) and irrespective of emphysema, chronic bronchitis or smoking status.1 The primary results showed that treatment with AstraZeneca and Amgen's TEZSPIRE® (tezepelumab) led to a 17% numerical reduction in the annual rate of moderate or severe COPD exacerbations compared to pl.
New data presented at ATS 2024 show the potential of TEZSPIRE to play a role in the future treatment of chronic obstructive pulmonary disease
WILMINGTON, Del.--(BUSINESS WIRE)--The Phase IIa COURSE trial was a proof-of-concept study in people with moderate to very severe chronic obstructive pulmonary disease (COPD) with a broad range of blood eosinophil counts (BEC) and irrespective of emphysema, chronic bronchitis or smoking status.1 The primary results showed that treatment with AstraZeneca and Amgen's TEZSPIRE® (tezepelumab) led to a 17% numerical reduction in the annual rate of moderate or severe COPD exacerbations compared to pl.
05/17 17:41 EST - reuters.com
Pfizer wins $107.5 million from AstraZeneca in US cancer drug patent trial
AstraZeneca owes Pfizer $107.5 million in damages, a Delaware federal jury said on Friday after finding that AstraZeneca's blockbuster lung cancer drug Tagrisso violated its Wyeth unit's patent rights.
Pfizer wins $107.5 million from AstraZeneca in US cancer drug patent trial
AstraZeneca owes Pfizer $107.5 million in damages, a Delaware federal jury said on Friday after finding that AstraZeneca's blockbuster lung cancer drug Tagrisso violated its Wyeth unit's patent rights.
05/16 06:10 EST - investorplace.com
7 Blue-Chip Stocks to Protect Your Wealth as the Economy Slows
For Q1 2024, GDP growth in the United States decelerated to 1.6% from 3.4% in the last quarter. There is no doubt that factors like high interest rates and geopolitical tensions have impacted growth.
7 Blue-Chip Stocks to Protect Your Wealth as the Economy Slows
For Q1 2024, GDP growth in the United States decelerated to 1.6% from 3.4% in the last quarter. There is no doubt that factors like high interest rates and geopolitical tensions have impacted growth.
05/16 02:17 EST - reuters.com
AstraZeneca's investigational COVID drug meets primary goals in late-stage study
AstraZeneca said on Thursday its investigational drug, sipavibart, met primary goals in preventing COVID-19 in immunocompromised patients in a late-stage trial.
AstraZeneca's investigational COVID drug meets primary goals in late-stage study
AstraZeneca said on Thursday its investigational drug, sipavibart, met primary goals in preventing COVID-19 in immunocompromised patients in a late-stage trial.
05/13 04:01 EST - proactiveinvestors.co.uk
Microsoft, Amazon and AstraZeneca invest billions in France
Microsoft Corp (NASDAQ:MSFT) said it will join a string of mega-cap companies in investing billions into the French economy after it pledged fresh investment into the European country. Some €4 billion will be invested into the nation by the tech giant as part of the annual ‘Choose France' business summit, Microsoft vice chair and president Brad Smith told reporters.
Microsoft, Amazon and AstraZeneca invest billions in France
Microsoft Corp (NASDAQ:MSFT) said it will join a string of mega-cap companies in investing billions into the French economy after it pledged fresh investment into the European country. Some €4 billion will be invested into the nation by the tech giant as part of the annual ‘Choose France' business summit, Microsoft vice chair and president Brad Smith told reporters.